|
Protein-bound paclitaxel is an injectable formulation of paclitaxel, which is used to treat breast cancer, lung cancer and pancreatic cancer among others. Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.〔〔 In this formulation, paclitaxel is bonded to albumin as a delivery vehicle. It is sometimes called nab-paclitaxel (with the "nab" syllable derived from "nanoparticle albumin–bound"). It is manufactured and sold in the United States by Abraxis BioScience under the trade name Abraxane where it is designated as an orphan drug as first-line treatment, in combination with gemcitabine, for the orphan disease "metastatic adenocarcinoma of the pancreas." This treatment was approved by the U.S. Food and Drug Administration (FDA) in January 2005 and the European Medicines Agency in January 2008 for breast cancer cases where cancer did not respond to other chemotherapy or has relapsed. In June 2010, positive results were published from a phase III trial in first-line non-small-cell lung cancer (NSCLC) when compared with solvent-based paclitaxel, and in October 2012 the FDA widened the approved use of Abraxane to include treatment for NSCLC. In September 2013, the FDA approved Abraxane for use in treating advanced pancreatic cancer as a less toxic (although less effective) alternative to FOLFIRINOX. Abraxane is registered on the Australian Register of Therapeutic Goods for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.〔Resolution 9190, Australian Drug Evaluation Committee, (258th meeting resolutions ), 6 June 2008.〕 Abraxane is also included on the Schedule of the Australian Pharmaceutical Benefits Scheme although〔Vines T, Faunce T, 'Assessing the safety and cost-effectiveness of early nanodrugs' J Law Med. 2009 May;16(5):822-45 (PMID: (19554862 ))〕 the manufacturer was unable to convince the independent Pharmaceutical Benefits Advisory Committee that the drug warranted a higher price than existing comparator drugs. 〔(PBAC, Public Summary Document ) (November 2008).〕 Abraxane was developed by VivoRx which became Abraxis BioScience as the first in its class of drugs to use the nanoparticle albumin bound (nab) technology platform.〔(nab Technology )〕 The originating patents are listed below: # Desai, N. P.; Soon-Shiong, P.; Sandford, P. A.; Grinstaff, M. W.; Suslick, K. S.; "Methods for In Vivo Delivery of Substantially Water Insoluble Pharmacologically Active Agents and Compositions Useful Therefor"; Aug. 8, 1995. # Desai, N. P.; Soon-Shiong, P.; Sandford, P. A.; Grinstaff, M. W.; Suslick, K. S.; "Composition Useful for In Vivo Delivery of Biologics and Methods Employing Same"; Mar. 12, 1996. # Desai, N. P.; Soon-Shiong, P.; Sandford, P. A.; Grinstaff, M. W.; Suslick, K. S.; "Methods for In Vivo Delivery of Substantially Water Insoluble Pharmacologically Active Agents and Compositions for the Use Thereof"; Oct. 1, 1996. # Grinstaff, M. W.; Soon-Shiong, P.; Wong, M.; Sandford, P. A.; Suslick, K. S.; Desai, N. P. "Methods for the Preparation of Blood Substitutes for In Vivo Delivery”; June 3, 1997. # Grinstaff, M. W.; Soon-Shiong, P.; Wong, M.; Sandford, P. A.; Suslick, K. S.; Desai, N. P. "Methods for the Preparation of Pharmaceutically Active Agents for In Vivo Delivery”; Sept. 9, 1997. In 2010, Abraxis was acquired by Celgene, which now markets Abraxane.〔(Celgene Completes Acquisition of Abraxis )〕 Total revenue from the sales of Abraxane for 2009 were $314.5 million.〔 In 2013, Abraxane was FDA approved for the treatment of pancreatic cancer. 〔(FDA Press Announcement )〕 In 2014, Abraxane's sales were $848 million, 31 percent year-over-year increase.〔(Celgene Press Announcement )〕 ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Protein-bound paclitaxel」の詳細全文を読む スポンサード リンク
|